Experimental hematology & oncology · 2026
Clinical outcomes and molecular features of CEBPA-mutated MPAL: a multi-center case series.
Письмо в редакциюНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Yirong, Luo Weijie, An Na, Zhang Xiaohan, Li Jianyun, Cao Yixuan, Zeng Yunxin, Ke Peng, Liu Lu, Yang Linlin, Luo Changru, Chen Shiyu, Yang Sitian, Peng Haoyu, Li Xiaoqing, Fan Jingchao, Dong Rujiao, Wen Bingbing, Du Xin, Wang Lixin, Weng Guangyang
Аннотация
Mixed phenotype acute leukemia (MPAL) is rare and aggressive, with no standard therapy. CEBPA mutations define favorable-risk AML, but their significance in MPAL is unknown. We reviewed eight CEBPA-mutated MPAL patients from five Chinese centers. Four received allo-HSCT in first complete remission and all remained alive and relapse-free (median follow-up of 24.0 months). Among four non-transplanted patients, three died (one refractory, two relapsed). Molecularly, four had biallelic inactivation and six had bZIP mutations. The high mortality among non-transplanted patients may suggest an aggressive nature of CEBPA-mutated MPAL, even in those with bZIP mutations, unlike its favorable-risk status in AML. Given the small sample and biases, no conclusions regarding optimal post-remission therapy can be drawn, though intensive strategies including transplantation may be considered based on this aggressiveness.